Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts

Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts

Minimal residual disease (MRD) is of major importance in onco-hematology, particularly in acute myeloid leukemia (AML). MRD measures the amount of leukemia cells remaining in a patient after treatment, and is an essential tool for disease monitoring, relapse prognosis, and guiding treatment decision...

Full description

Bibliographic Details
Main Authors:	Mathias Chea, Lucie Rigolot, Alban Canali, Francois Vergez
Format:	Article
Language:	English
Published:	MDPI AG 2024-02-01
Series:	International Journal of Molecular Sciences
Subjects:	MRD AML flow cytometry PCR NGS LAIP
Online Access:	https://www.mdpi.com/1422-0067/25/4/2150

Similar Items

Identification of Leukemia-Associated Immunophenotypes by Databaseguided Flow Cytometry Provides a Highly Sensitive and Reproducible Strategy for the Study of Measurable Residual Disease in Acute Myeloblastic Leukemia
by: Paula Piñero, et al.
Published: (2022-08-01)

Novel Tools for Diagnosis and Monitoring of AML
by: Francesca Guijarro, et al.
Published: (2023-05-01)

MRD in AML: The Role of New Techniques
by: Maria Teresa Voso, et al.
Published: (2019-07-01)

Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation
by: Francesco Buccisano, et al.
Published: (2021-03-01)

Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group
by: Maddalena Benetton, et al.
Published: (2022-06-01)

Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context
by: Nikhil Patkar, et al.
Published: (2019-06-01)

Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia
by: Francesco Buccisano, et al.
Published: (2018-06-01)

Eradication of Measurable Residual Disease in AML: A Challenging Clinical Goal
by: Paolo Bernasconi, et al.
Published: (2021-06-01)

Pharmacologic Strategies for Post-Transplant Maintenance in Acute Myeloid Leukemia: It Is Time to Consider!
by: Iman Abou Dalle, et al.
Published: (2022-03-01)

Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection
by: Kritika Srinivasan Rajsri, et al.
Published: (2023-05-01)

Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients
by: Susanna Grassi, et al.
Published: (2020-06-01)

Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
by: Ing S. Tiong, et al.
Published: (2023-03-01)

Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker
by: Nasrin Alizad Ghandforoush, et al.
Published: (2016-06-01)

Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia
by: Tali Azenkot, et al.
Published: (2022-07-01)

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future
by: Alejandro Medina-Herrera, et al.
Published: (2023-07-01)

Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review
by: Lemei Zhu, et al.
Published: (2023-08-01)

Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year
by: Riana van der Linde, et al.
Published: (2023-10-01)

Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool
by: Sara Galimberti, et al.
Published: (2022-05-01)

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
by: Donata Backhaus, et al.
Published: (2021-11-01)

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
by: Irene Della Starza, et al.
Published: (2023-01-01)

Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission
by: Xi Jia, et al.
Published: (2024-02-01)

Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study
by: Teresa Caballero-Velázquez, et al.
Published: (2023-03-01)

Liquid biopsies and minimal residual disease in myeloid malignancies
by: Sabine Allam, et al.
Published: (2023-05-01)

MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?
by: Ilias Pessach, et al.
Published: (2022-09-01)

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
by: Jonas S. Heitmann, et al.
Published: (2023-08-01)

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia
by: Christian M. Vonk, et al.
Published: (2021-10-01)

Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives
by: Domenico Russo, et al.
Published: (2020-06-01)

Flow cytometry in clinical practise
by: Mona H. Fenstad, et al.
Published: (2012-10-01)

Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges
by: Xiaofen Wen, et al.
Published: (2023-10-01)

Minimal residual disease detection in Tunisian B-acute lymphoblastic leukemia based on immunoglobulin gene rearrangements
by: S. Besbes, et al.

Normalization of NPM1 mutant transcript to the wild‐type transcript
by: Lawrence J. Jennings
Published: (2022-11-01)

Digital PCR as a New Method for Minimal Residual Disease Monitoring and Treatment Free Remission Management in Chronic Myeloid Leukemia Patients: Is It Reliable?
by: Simona Bernardi, et al.
Published: (2022-12-01)

Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia
by: Klaus Geissler, et al.
Published: (2020-08-01)

Quality Assessment of a Large Multi-Center Flow Cytometric Dataset of Acute Myeloid Leukemia Patients—A EuroFlow Study
by: Anne E. Bras, et al.
Published: (2022-04-01)

Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms
by: Paula Aguirre-Ruiz, et al.
Published: (2020-11-01)

Revealing the Mysteries of Acute Myeloid Leukemia: From Quantitative PCR through Next-Generation Sequencing and Systemic Metabolomic Profiling
by: Cristina Panuzzo, et al.
Published: (2022-01-01)

Low IL7R Expression at Diagnosis Predicted Relapse in Adult Acute Myeloid Leukemia Patients With t(8;21)
by: Nan Xu, et al.
Published: (2022-07-01)

Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis
by: Jesse M. Tettero, et al.
Published: (2022-10-01)

Minimal Residual Disease, Metastasis and Immunity
by: Jordi Badia-Ramentol, et al.
Published: (2021-01-01)

Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response
by: Hong Yuen Wong, et al.
Published: (2019-01-01)